Floatz logo

Ampreloxetine

Parkinson Disease

Theravance BiopharmaSmall moleculePhase 3Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
65/ 100

Competitive context

256 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Istradefylline
Georgetown University
Phase 4BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Pardoprunox
Abbott Products
Phase 3BBB

View all 50 →

Same molecule, other indications

Ampreloxetine is also rated in:

primary orthostatic hypotensionDormant
CCC
Indicative ·
54 / 100
View asset →
multiple system atrophyDormant
CCC
Indicative ·
51 / 100
View asset →
pure autonomic failureDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →